Medicine importers may recover VAT paid on qualified drugs where the Tax Code grants exemption from January 1, 2020 despite later BIR circular dates.

Importers of VAT-exempt prescription medicines should not automatically accept a refund denial based on a later BIR circular if the Tax Code itself grants the exemption from an earlier date. In a January 2025 decision, the Court of Tax Appeals allowed a pharmaceutical importer to recover the remaining VAT it paid on imports of medicines for diabetes, high cholesterol, and hypertension, holding that the statutory exemption beginning January 1, 2020 prevailed over administrative issuances that referred to later effectivity dates.

Background: VAT Paid on Imported Prescription Medicines

The taxpayer was a Philippine branch of a foreign corporation licensed to do business in the Philippines and registered for VAT. It imported prescription medicines used for the treatment of diabetes, high cholesterol, and hypertension during the period from January 2020 to April 2020. VAT was paid on those importations, and the taxpayer later filed administrative claims for refund totaling P33,730,490.83 under Sections 109, 204(C), and 229 of the National Internal Revenue Code, as amended.

The refund claim had two components: P6,290,154.00 for imports from January 1 to January 22, 2020, and P27,440,336.83 for imports from January 23 to April 30, 2020. The BIR denied the first component because the medicines were imported before what the BIR considered the relevant effectivity date under its circulars and regulations. For the second component, the BIR later issued a VAT Refund Notice granting P19,140,829.83 but disallowing P8,299,507.00. The taxpayer brought the dispute to the Court of Tax Appeals (CTA Case No. 10718).

The Core Issue: When Did the VAT Exemption Begin?

The dispute turned on the effectivity of the VAT exemption under Section 109(1)(AA)(i) of the Tax Code, as amended by Republic Act No. 11467. The statutory text provides that the sale or importation of prescription drugs and medicines for diabetes, high cholesterol, and hypertension is exempt from VAT beginning January 1, 2020.

The BIR relied on administrative issuances that referred to later dates. RMC No. 62-2020 published the list of prescription drugs and medicines for diabetes, high cholesterol, and hypertension exempt from VAT beginning January 27, 2020. RMC No. 113-2020 later clarified that Republic Act No. 11467 took effect on January 23, 2020. The BIR position, in substance, was that imports made before the later administrative effectivity dates remained subject to VAT.

The Court’s Ruling: The Law Prevails Over Revenue Circulars

The Court ruled that the importation of prescription drugs and medicines for diabetes, high cholesterol, and hypertension was VAT-exempt beginning January 1, 2020. It emphasized that Republic Act No. 11467 expressly stated the date when the VAT exemption would begin. That statutory date could not be displaced by revenue memorandum circulars or implementing rules referring to a later effectivity date.

The decision applied the settled principle that, in case of conflict, the law prevails over administrative regulations. Administrative issuances may implement the law, but they cannot override, amend, broaden, or restrict the statute they are supposed to carry out. Revenue memorandum circulars, in particular, cannot modify the Tax Code.

The Court also recognized that a tax statute may operate retroactively when the legislative intent is clear. Here, the Court found the intent clear because the statute itself identified January 1, 2020 as the beginning date of the VAT exemption for the covered prescription medicines.

Refund Requirements: Timeliness, Proof of Payment, and Non-Utilization

The taxpayer still had to satisfy the requirements for a refund of erroneously or illegally paid tax. Under Sections 204(C) and 229 of the Tax Code, both the administrative claim and the judicial claim must be filed within two years from payment of the tax. The Court found that the taxpayer’s administrative claims filed on October 18, 2021 and its judicial claim filed on January 5, 2022 were timely in relation to VAT payments made from January to April 2020.

The Court further examined whether VAT had actually been paid on the covered importations and whether the taxpayer had already used the amounts as input tax credits. The taxpayer presented importation documents, including Bureau of Customs single administrative documents, statements of settlement of duties and taxes, assessment notices, commercial invoices, and a VAT payment certification. The imported products included medicines with generic names such as sitagliptin, metformin with sitagliptin, losartan, amlodipine, hydrochlorothiazide, simvastatin, and ezetimibe, which were included in the VAT-exempt list for covered medicines.

The Court also found that the VAT amounts were reported as purchases not qualified for input tax, not as input tax credits. This mattered because a taxpayer cannot recover VAT through refund if it has already carried over, credited, or utilized the same amount in its VAT returns. On the evidence, the Court found that the VAT subject of the claim had not been claimed as input tax credit.

Amount Granted: Partial Refund Because the BIR Already Approved Part of the Claim

The Court found that the taxpayer established a total refund claim of P33,730,490.83 for VAT paid on the importation of qualified prescription medicines. However, because the BIR had already granted P19,140,829.83 through a VAT Refund Notice, the Court awarded only the remaining balance.

The Commissioner was ordered to refund P14,589,661.00, representing the VAT erroneously paid on the importation of medicines intended for the treatment of persons with diabetes, high cholesterol, and hypertension for the period from January 7, 2020 to April 1, 2020. The petition was therefore partially granted, not because the taxpayer failed to prove the VAT exemption, but because part of the claim had already been administratively approved.

Practical Takeaways for Taxpayers and Importers

First, taxpayers should compare BIR issuances against the actual text of the Tax Code. A BIR circular may guide implementation, but it cannot defeat a clear statutory exemption. Where an administrative issuance narrows a benefit expressly granted by law, there may be a basis to challenge a denial before the Court of Tax Appeals.

Second, medicine importers and distributors should preserve complete importation and payment records. Refund litigation is evidence-heavy. Import entries, customs assessments, settlement documents, invoices, VAT payment certifications, and VAT returns must be internally consistent and must show that the imported goods fall within the statutory exemption.

Third, taxpayers must track the two-year prescriptive period from the actual dates of tax payment. For erroneous payment claims under Sections 204(C) and 229, filing with the BIR is not enough if the judicial claim is filed late. Both administrative and court actions must be filed within the applicable two-year period.

Fourth, taxpayers must avoid double recovery. A refund claim becomes vulnerable if the same VAT was claimed as input tax credit, carried over, or otherwise utilized. Before filing, taxpayers should reconcile their refund schedules with their monthly and quarterly VAT returns.

How Ablola, Saribong & Gueco Can Assist

Ablola, Saribong & Gueco assists taxpayers, importers, pharmaceutical companies, customs brokers, and corporate finance teams in evaluating VAT refund claims, preparing administrative refund filings, responding to BIR denials, and litigating tax disputes before the Court of Tax Appeals. Our tax litigation practice can review whether a tax payment was legally due, whether the claim remains within the prescriptive period, and whether the documentary evidence is sufficient for court.

For businesses dealing with VAT refund denials, customs-related VAT payments, pharmaceutical tax exemptions, or disputed BIR interpretations, contact Ablola, Saribong & Gueco through MakatiLawFirm.com to discuss the available legal remedies and litigation strategy.


Leave a Comment

Your email address will not be published. Required fields are marked *